organization · Reporting owner
Merck Global Health Innovation Fund, LLC
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| electroCore, Inc.ECOR · Entity 6900 | 10% owner | June 21, 2018 | June 22, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
electroCore, Inc.
Report date June 21, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,346,032 |
Reported balance
After 2018-06-21 transaction · row 1
1 source rowRow 1 · 2018-06-21 · Purchase · Acquired 166,666 · Balance 3,346,032 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CapForce Inc.
Report date December 31, 2017 · Filed February 08, 2018
Jointly reported with Merck & Co., Inc., Merck Sharp & Dohme Corp.
Section 16 reporting ended · disclosed 2018-02-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $19.50 · Expires 2022-06-28 | IndirectSee footnote | 13,120 |
Reported balance
After 2017-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-28 · Grant · Acquired 13,120 · Balance 13,120 F1: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018. F2: These securities are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. |
Filing footnotes · ownership attribution and instrument terms
F1: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018.
F2: These securities are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2018 Filed Jun 22, 2018 19:23 UTC | electroCore, Inc. ECOR · Entity 6900 | PurchaseCommon Stock | 166,666 | $15.00 | $2,499,990.00 |
DisclosureSEC source: 0001104659-18-041862 · a4.xml · nonDerivative · entry 1 Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,346,032 Read SEC document |
| June 28, 2017 Filed Feb 8, 2018 21:05 UTC | CapForce Inc. OPGN · Entity 9776 | GrantWarrant to Purchase Common Stock · Derivative | 13,120 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0000899243-18-003274 · doc5.xml · derivative · entry 1 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,120 Underlying: Common Stock · 13,120 shares Expires 2022-06-28 F1 · derivative.exercise_price: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018. F1 · shares: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018. F1 · derivative.underlying_shares: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018. F1 · balance_after: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018. F2 · ownership.nature: These securities are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
| June 27, 2016 Filed Jun 29, 2016 20:05 UTC | CapForce Inc. OPGN · Entity 9776 | PurchaseWarrants · Derivative | 2,050,821 | Not disclosed Strike: $1.31 | Not disclosed |
DisclosureSEC source: 0000899243-16-023850 · doc4.xml · derivative · entry 2 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,950,821 Underlying: Common Stock · 2,050,821 shares Expires 2021-06-27 F1 · price: The reported securities were included within units ("Units") with each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the "Common Stock") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit. F2 · ownership.nature: These securities are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
| June 27, 2016 Filed Jun 29, 2016 20:05 UTC | CapForce Inc. OPGN · Entity 9776 | GrantCommon Stock | 2,734,427 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-023850 · doc4.xml · nonDerivative · entry 1 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,413,449 F1 · price: The reported securities were included within units ("Units") with each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the "Common Stock") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit. F2 · ownership.nature: These securities are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
| May 19, 2016 Filed May 24, 2016 20:41 UTC | CapForce Inc. OPGN · Entity 9776 | PurchaseCommon Stock and Warrants (Obligation to buy Units) · Derivative | 2,734,427 | Not disclosed Strike: $1.14 | Not disclosed |
DisclosureSEC source: 0000899243-16-020819 · doc4.xml · derivative · entry 3 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,685,248 Underlying: Common Stock · 4,785,248 shares Expires not disclosed F3 · price: Represents future obligation of MGHIF to purchase additional Units for a purchase price of $1.14375 per Unit within 60 days and subject to stockholder consent and notice to stockholders of same (including the filing of Schedule 14C and the twenty day waiting period), pursuant to the Amended and Restated Securities Purchase Agreement entered into on May 18, 2016. F3 · derivative.exercise_date: Represents future obligation of MGHIF to purchase additional Units for a purchase price of $1.14375 per Unit within 60 days and subject to stockholder consent and notice to stockholders of same (including the filing of Schedule 14C and the twenty day waiting period), pursuant to the Amended and Restated Securities Purchase Agreement entered into on May 18, 2016. F3 · derivative.expiration_date: Represents future obligation of MGHIF to purchase additional Units for a purchase price of $1.14375 per Unit within 60 days and subject to stockholder consent and notice to stockholders of same (including the filing of Schedule 14C and the twenty day waiting period), pursuant to the Amended and Restated Securities Purchase Agreement entered into on May 18, 2016. F2 · ownership.nature: These shares are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
| May 19, 2016 Filed May 24, 2016 20:41 UTC | CapForce Inc. OPGN · Entity 9776 | PurchaseWarrants · Derivative | 900,000 | Not disclosed Strike: $1.31 | Not disclosed |
DisclosureSEC source: 0000899243-16-020819 · doc4.xml · derivative · entry 2 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2021-05-19 F1 · price: The reported securities are included within units ("Units") each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the "Common Stock") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit. F2 · ownership.nature: These shares are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
| May 19, 2016 Filed May 24, 2016 20:41 UTC | CapForce Inc. OPGN · Entity 9776 | GrantCommon Stock | 1,200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-020819 · doc4.xml · nonDerivative · entry 1 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,679,022 F1 · price: The reported securities are included within units ("Units") each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the "Common Stock") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit. F2 · ownership.nature: These shares are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.